Status:

NOT_YET_RECRUITING

A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss

Lead Sponsor:

Stanford University

Conditions:

Lactation Suppressed

Eligibility:

FEMALE

18-55 years

Phase:

PHASE2

Brief Summary

Most patients seeking abortion care or management of pregnancy loss in the second trimester will lactate, which can be physically and emotionally painful. The efficacy of a one-time dose of cabergolin...

Detailed Description

Most people do not expect breast engorgement following a second-trimester pregnancy loss yet nearly all report bothersome symptoms. Prolactin is the primary hormone responsible for milk production. Th...

Eligibility Criteria

Inclusion

  • Pregnant people, ages 18 years or older
  • Intrauterine pregnancy between 16/0-25/6 weeks of gestation age (by ultrasound dating performed prior to or same day of enrollment visit)
  • Consented for an induced, elective abortion or undergoing management of fetal demise
  • English or Spanish speaking
  • Able to consent for a research study, literate in English or Spanish
  • Willing to comply with study procedures and follow-up
  • Access to smart phone throughout study

Exclusion

  • Prior mastectomy (breast reduction or chest masculinization surgery acceptable)
  • Currently breastfeeding
  • Currently receiving dopamine agonist or antagonist therapy for other indication leg syndrome)
  • Contraindication to cabergoline (as per package insert)
  • Uncontrolled hypertension - defined as baseline BP \> 160/110, or chronic hypertension requiring more than one baseline medication, or current pregnancy-induced hypertension spectrum disorders (gestational hypertension, preeclampsia, eclampsia)
  • History of cardiac valvular disorders or valvular repair
  • History of pulmonary, pericardial, or retroperitoneal fibrotic disorders

Key Trial Info

Start Date :

July 1 2026

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2027

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT06909123

Start Date

July 1 2026

End Date

July 1 2027

Last Update

December 12 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss | DecenTrialz